Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday. The AIM-traded firm said the completion of the single ascending dose (SAD) phase and the food effect study marked progress in the development of the dual TYK2/JAK1 kinase inhibitor.

It said the phase 1a trial focussed on assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of SDC-1801 in healthy subjects.

Comprising single and multiple ascending dose studies, as well as a food effects study, the trial aimed to provide crucial insights into the therapeutic potential of SDC-1801.

Following the dosing of the final subjects in the SAD phase, preliminary data analysis revealed promising results.

The safety review committee's assessment indicated a favourable safety profile for SDC-1801, supporting its potential for once-daily oral dosing.

No serious adverse events were reported, suggesting the compound's safety and tolerability.

Additionally, the completion of the food effect study demonstrated that SDC-1801's blood levels remained consistent regardless of food intake.

That finding offered flexibility in dosing schedules for future clinical studies, enhancing the drug's usability and convenience.

While the multiple ascending dose study was ongoing, the company said it anticipated the availability of full safety data in the first half of 2024.

Pending satisfactory results and contingent on financing, regulatory approvals and recruitment, Sareum said it was planning to initiate a phase 1b clinical study.

The next phase aimed to enrol up to 24 psoriasis patients, with completion expected by the end of 2024.

"We're pleased to announce that Sareum has cleared an important milestone in this trial," said chief executive officer Dr Tim Mitchell.

"We are encouraged by the preliminary data from the SAD and food effect parts of the phase 1a trial for SDC-1801, which support our confidence in the trial and the broader clinical strategy."

Dr Mitchell said while they were preliminary results, if the firm continued to see the positive safety profile and pharmacokinetic data seen so far, that would underpin our planning for the phase 1b part of the study and beyond.

"We look forward to the data from the multiple ascending dose part of this trial, which will help us advance towards this critical next point in the study."

At 1257 GMT, shares in Sareum Holdings were up 11.73% at 41.9p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Vector Capital reports robust year-end financial position
(Sharecast News) - Commercial lender Vector Capital reported continued growth in shareholders' equity while maintaining dividends and implementing prudent bad debt provision policies in its full-year results on Friday.
Quadrise posts progress with Utah partner Valkor
(Sharecast News) - Quadrise updated the market on its collaboration with Valkor Technologies in Utah on Friday, targeting the supply of low sulphur 'MSAR' and 'bioMSAR' to the marine and power sector.
Clean Power Hydrogen reports solid full-year progress
(Sharecast News) - UK-based green hydrogen technology company Clean Power Hydrogen (CPH2) reported solid progress towards the commercial rollout of its membrane-free electrolyser (MFE) technology in its final results on Friday, driven by a revamped engineering team.
Diesel generators arrive for Goldplat's South Africa operations
(Sharecast News) - South Africa and Ghana-focussed Goldplat announced the arrival of diesel generators at its South African operations on Friday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.